Global Innovative Platforms (GIPL) Current Deferred Revenue (2025)
Global Innovative Platforms' (GIPL) quarterly Current Deferred Revenue came in at $55500.0 in Q4 2025.
Powered by 
Analysis
Global Innovative Platforms (GIPL) Current Deferred Revenue (2025) Analysis & Trends
Global Innovative Platforms has disclosed Current Deferred Revenue across 1 years of filings, most recently posting $55500.0 for Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.57 Bn | 40.38 Bn | 779.09 Mn |
| 2 | Zoetis | 30.57 Bn | 28.90 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.47 Bn | 10.94 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.43 Bn | 1.35 Bn | 134.40 Mn |
| 5 | Immucell | 87.38 Mn | 78.52 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 64.40 Mn | 57.30 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |